VER Share PerformanceMore
|52 week high||39.335 02/11/16|
|52 week low||10.000 12/10/17|
|52 week change||-25.250 (-66.01%)|
|4 week volume||7,744,858 25/09/17|
Latest News« previous» nextMore
29/09/2017 - 07:00 RNS
RNS Number: 8539R Vernalis PLC 29 September 2017 BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION VERNALIS PLC (the "Company") 29 September 2017 Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements...
12/09/2017 - 07:38 StockMarketWire
Vernalis reported revenue of 20.8m (2016: 12m), which was ahead of market expectations in the year to 30 June 2017. US CO...
12/09/2017 - 07:00 RNS
RNS Number: 4293Q Vernalis PLC 12 September 2017 12 September 2017 LSE: VER Vernalis plc Results Announcement for the year ended 30 June 2017 Tuzistra XR prescriptions growing steadily In-house salesforce to promote both Tuzistra XR and Moxatag for the coming season Independent market research continues to show significant market opportunity for co...
07/08/2017 - 07:00 RNS
RNS Number: 2148N Vernalis PLC 07 August 2017 07 August 2017 LSE: VER FDA Issues a Complete Response Letter on CCP-08 NDA Vernalis plc announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08. A CRL is issued by the FDA when it has comple...
28/07/2017 - 09:30 StockMarketWire
Cantor Fitzgerald today reaffirms its buy investment rating on Vernalis PLC (LON:VER) and cut its price target to 81p (fr...
18/07/2017 - 07:11 StockMarketWire
Vernalis said total revenues are expected to be ahead of current market expectations. This was principally as a result of lar...
18/07/2017 - 07:00 RNS
RNS Number: 2825L Vernalis PLC 18 July 2017 18 July 2017 LSE: VER Year-End Trading Update and Notice of Full Year Results Continued steady growth of Tuzistra XR annualised prescription run rate through drug's second cough cold season; similar growth rate expected for 2017/18 season Plan to resume full promotion of Moxatag in September Continued to adv...
30/06/2017 - 07:00 RNS
RNS Number: 6343J Vernalis PLC 30 June 2017 TOTAL VOTING RIGHTS VERNALIS PLC (the "Company") 30 June 2017 Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,445,230 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury. The total number o...
|Dividend yield||0 %|
Latest discussion posts More
“Remember my post back in April ? Not many here since . Chart don't lie , it didn't then it isn't now . Though it may be basing . Or about to . In other words we ...”▼
“Recent RNS from Vernalis: "Total revenues are expected to be ahead of current market expectations, principally as a result of larger than expected research collaboration ...”▼
“ Just need to time the close now ! Lurking on these beautiful trending stocks you can bet is where you can find me ! Its all I look out for 24/7 !! Just need the time to ...”▼
Codes & Symbols
|Symbols||VER, LSE:VER, VER.L, VER:LN, LON:VER, XLON:VER|